TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #239999

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client ELYVERA

Sample Triple Receptor Agonist 10mg

Manufacturer Distributed by ELYVERA

Batch TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)

Results >

Retatrutide	11.10 mg
Purity	99.643%
Total Aggregate	0.101%

Comments >

Analysis conducted > 09 OCT 2026

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

RN3SSFJN7VDV

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #240005

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client ELYVERA

Sample Triple Receptor Agonist 10mg

Manufacturer Distributed by ELYVERA

Batch TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

Heavy Metals Analysis

Results >

As	not detected.
Cd	not detected.
Pb	not detected.

Comments >

Hg: not detected.

Analysis conducted > 09 OCT 2026

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

6EP6H4R8S1RL

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #240003

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client	ELYVERA
Sample	Triple Receptor Agonist 10mg
Manufacturer	Distributed by ELYVERA
Batch	TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

LCMS Screening For Peptide Contamination

Results >

LCMS screening	

Comments >

LCMS analysis identified the presence of mannitol (peak 1), retatrutide and its degradation products (peak 2). LCMS spectra are attached. No significant contamination detected.

Analysis conducted > 12 OCT 2026

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

6FA8IV6ZHNVM

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #240001

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client ELYVERA

Sample Triple Receptor Agonist 10mg

Manufacturer Distributed by ELYVERA

Batch TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

TFA analysis

Results >

TFA	not detected

Comments >

Analysis conducted > 12 OCT 2026

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

ZAP511R9PZRU

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #240002

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client	ELYVERA
Sample	Triple Receptor Agonist 10mg
Manufacturer	Distributed by ELYVERA
Batch	TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

Endotoxin Analysis

Results >

Endotoxin	2.814 EU/Vial.

Comments >

Analysis conducted > 09 OCT 2026

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

MYXKID5JJP81

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #240004

Testing ordered > 30 SEP '26

Sample received > 08 OCT '26

Client ELYVERA

Sample Triple Receptor Agonist 10mg

Manufacturer Distributed by ELYVERA

Batch TRA-10-2026-002

Sample description >

See picture or pictures attached.

Tests requested >

Sterility Testing

Results >

TAMC	PASS
TYMC	PASS

Comments >

Analysis conducted > 27 OCT 2026

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

X5UIIVAE29D6

JANOSHIK



JANOSHIK


SHIMADZU LabSolutions

Analysis Report

<Sample Information>

Sample Name	: 32584-1 Reta 10mg +LCMS scr, +dimer +TFA analysis		
Sample ID	: 020		
Data Filename	: 32584-1 Reta 10mg +LCMS scr, +dimer +TFA analysis_002.lcd		
Method Filename	: C18- GLP1.lcm		
Batch Filename	: 09_10_2026_01.lcb		
Vial #	: 3-9	Sample Type	: Unknown
Injection Volume	: 0.5 uL		
Date Acquired	: 09.10.2026 12:22:47	Acquired by	: System Administrator
Date Processed	: 09.10.2026 13:37:30	Processed by	: System Administrator

<Chromatogram>



<Peak Table>

PDA Ch1 280nm

Peak#	Ret. Time	Area	Conc.	Unit	Name	Area%
1	4.806	258	0.00			0.280
2	4.854	91848	11.10	mg	Retatrutide	99.643
3	5.014	71	0.00			0.078
Total		92177				100.000


SHIMADZU LabSolutions

Analysis Report

<Sample Information>

Sample Name	: 32584-1 Reta 10mg +LCMS scr, +dimer +TFA analysis		
Sample ID	:		
Data Filename	: 32584-1 Reta 10mg +LCMS scr, +dimer +TFA analysis_007.lcd		
Method Filename	: DIMER AND AGGREGATE METHOD - Vzorek.lcm		
Batch Filename	: 20261009-1+ Shutdown.lcb		
Vial #	: 1-21	Sample Type	: Unknown
Injection Volume	: 5 uL		
Date Acquired	: 09.10.2026 16:38:40	Acquired by	: admin
Date Processed	: 12.10.2026 8:25:40	Processed by	: admin

<Chromatogram>



Peak Table

PDA Ch1 220nm

Peak#	Ret. Time	Name	Area%
1	9.223		0.101
2	9.679		99.899
Total			100.000

LC-MS Screening Summary

Retatrutide (10 mg nominal) | Sample 32584-1

Client-facing analytical summary

Summary

LC-MS screening identifies retatrutide in the main peptide region at approximately 7.29 min, with additional ions indicating retatrutide degradation products. Mannitol is present in the early-eluting peak. This qualitative analysis does not determine purity.

Parameter	Observation
Analysis	ESI(+) LC-MS; full-scan MS1; m/z approx. 147-2000.
Sample	32584-1; Reta, nominal 10 mg.
Main peptide-related region	Approx. 7.25-7.38 min; apex ~7.29 min.
Representative spectrum	RT 7.285 min.
Prominent ions	m/z 1580.1, 1587.4, 1594.6 (putative 3+ series); 1184.5 (4+).
Reference comparison	Retatrutide nominal mass ~4731 Da; 3+ ~1578.1; 4+ ~1183.8.
Overall assessment	Retatrutide identified; retatrutide degradation products present.

Chromatographic profile

Figure 1. MS1 total ion chromatogram (TIC) for sample 32584-1.





Figure 1a. Extracted-ion chromatogram (m/z 1580.1).



Chromatographic comment.

The first peak at RT ~0.27 min (m/z ~205) is mannitol. The principal peptide-related region elutes near RT 7.29 min. Column-derived background peaks are not included in the sample assessment.

Mass spectrum of the principal region

Figure 2. Representative MS1 mass spectrum at RT 7.285 min.





Figure 2a. Expanded ion series (m/z 1571-1608).



Interpretation

• The main peptide-related region elutes at ~7.29 min. Ions at m/z 1580.1, 1587.4 and 1594.6 form a series spaced by ~7.3 m/z, compatible with differing sodium adducts of a triply charged species.

• Retatrutide (~4731 Da) has approximate theoretical ions at m/z 1578.1 (3+) and 1183.8 (4+). The ion pattern supports retatrutide identification, alongside shifted ions consistent with retatrutide degradation products. Individual degradation structures are not determined from MS1 alone.

• The peak at RT ~0.27 min (m/z ~205) is mannitol. The column-derived signal is excluded from sample assessment.


Conclusion

Retatrutide is identified in the sample, together with its degradation products. Mannitol is also present. This qualitative screening does not establish degradation product structures or sample purity.

Analytical note

Qualitative screening only; not a quantitative assay or certificate of purity.

D:/12.10/32584-1 TFAanalysis_Fluorine-1-1.jdf
32584-1 TFAanalysis



JANOSHIK
19F 1D
JANOSHIK